10-Q: Actinium Pharmaceuticals Reports Third Quarter 2024 Results, Provides Update on Clinical Programs

Actinium Pharmaceuticals' Q3 2024 report details financial results and provides updates on the clinical development of Iomab-B, Actimab-A, and Iomab-ACT, including regulatory feedback and strategic partnership efforts.

Summary

• Actinium Pharmaceuticals reported no revenue for the three and nine months ended September 30, 2024.
• The company's net loss for the three months ended September 30, 2024, was $11.6 million, compared to a net loss of $13.3 million for the same period in 2023.
• For the nine months ended September 30, 2024, the net loss was $31.6 million, a decrease from the $39.5 million loss in the same period of 2023.
• Research and development expenses decreased to $9.8 million for the three months ended September 30, 2024, from $11.6 million in 2023, and to $25.2 million for the nine months ended September 30, 2024, from $30.6 million in 2023.
• General and administrative expenses increased slightly to $2.8 million for the three months ended September 30, 2024, from $2.7 million in 2023, but decreased to $9.4 million for the nine months ended September 30, 2024, from $11.0 million in 2023.
• The company had cash and cash equivalents of $78.7 million as of September 30, 2024, compared to $76.7 million at the end of 2023.
• Actinium sold 3.5 million shares of common stock for net proceeds of $29.3 million during the nine months ended September 30, 2024.
• The FDA has indicated that the SIERRA trial alone is not sufficient for a BLA filing for Iomab-B and requires an additional head-to-head trial and a dose optimization trial.
• Actinium is seeking a strategic partner for Iomab-B in the U.S. to advance the required clinical trials.
• The company is progressing with the development of Actimab-A, including a Phase 2/3 clinical trial in combination with CLAG-M, and is collaborating with the NCI under a CRADA.
• Iomab-ACT is being developed for cell and gene therapies, with ongoing clinical trials and a new trial cleared by the FDA to study it with a commercial CAR-T therapy.

Sentiment

Score: 4

Explanation: The document presents mixed signals. While there is progress in some areas, such as the development of Actimab-A and Iomab-ACT, the FDA's rejection of the SIERRA trial results for Iomab-B and the need for additional trials is a significant setback. The company's financial position is stable, but the need for a strategic partner and the reduction in headcount raise concerns. Overall, the sentiment is cautiously negative.

Positives

• The company's net loss decreased year-over-year for both the three and nine-month periods.
• Cash and cash equivalents increased slightly, providing a stable financial position.
• The company has aligned with the FDA on a Phase 2/3 trial design for Actimab-A, which is expected to reduce time and resources.
• Actinium has secured a CRADA with the NCI, which will provide extensive support for and accelerate the development of Actimab-A.
• The company's proprietary technology for producing Ac-225 in a cyclotron has the potential to significantly reduce costs.
• The company has received FDA clearance for a new clinical trial to study Iomab-ACT with a commercial CAR-T therapy.

Negatives

• The FDA has determined that the SIERRA trial alone is not adequate to support a BLA filing for Iomab-B, requiring an additional head-to-head trial and a dose optimization trial.
• The company has no commercial revenue and continues to operate at a net loss.
• The company is dependent on third-party manufacturers for its drug supplies.
• The company is seeking a strategic partner for Iomab-B in the U.S., indicating a need for external support to advance the program.
• The company has reduced its headcount by approximately 20%, primarily in clinical and CMC groups, which may impact operations.

Risks

• The FDA's requirement for an additional head-to-head trial for Iomab-B introduces significant uncertainty and potential delays.
• The company's reliance on third-party manufacturers for drug supplies poses a risk of supply chain disruptions.
• The company's ability to secure a strategic partner for Iomab-B is uncertain.
• The company's reduced headcount may impact its ability to execute its operating plan.
• The company's dependence on the clinical, regulatory and commercial success of Iomab-B, Actimab-A, Iomab-ACT and other pipeline candidates is a significant risk.
• The company's business is subject to cybersecurity risks.
• The company's clinical trials may fail to demonstrate adequately the efficacy and safety of its product candidates.
• The company's patent position is highly uncertain and involves complex legal and factual questions.
• The company is highly dependent on its key personnel, and the demand for talent in the biotechnology industry is highly competitive.

Future Outlook

Actinium expects its existing resources to fund planned operations for more than 12 months following the date of the report and is actively seeking a strategic partner for Iomab-B in the U.S. to advance the head-to-head clinical trial or other clinical development activity for Iomab-B.

Management Comments

• Actinium believes it has aligned with the FDA on the patient population for a head-to-head Phase 3 clinical trial to further evaluate allogeneic BMT using Iomab-B plus a reduced intensity conditioning regimen of Flu/TBI versus allogeneic BMT using reduced intensity conditioning comprised of cyclophosphamide plus Flu/TBI in all adult patients aged 18 and above with active AML with blasts counts greater than 5% and less than 20%.
• Actinium is actively seeking a strategic partner for Iomab-B in the U.S. to advance the head-to-head clinical trial or other clinical development activity for Iomab-B.
• Actinium expects to commence patient enrollment of the Iomab-ACT commercial CAR-T trial in the first quarter of 2025 and generate proof of concept clinical data by year end 2025.

Industry Context

The report highlights Actinium's focus on radiotherapeutics, a growing area in cancer treatment, and its efforts to address unmet needs in relapsed or refractory cancers. The company's approach aligns with the trend towards targeted therapies and personalized medicine, particularly in hematology and oncology. The company is also positioning itself in the rapidly growing cell and gene therapy market with its Iomab-ACT program.

Comparison to Industry Standards

• Actinium's focus on Antibody Radiation Conjugates (ARCs) places it in a niche market within the broader radiopharmaceutical industry, which includes companies like Novartis (Pluvicto, Lutathera) and Bayer (Xofigo) that focus on small molecule radioligands.
• Unlike these companies, Actinium is developing biologics, which have different regulatory pathways and market dynamics, including longer exclusivity periods.
• The company's proprietary Ac-225 production technology aims to address a key industry challenge: the limited supply and high cost of this isotope, which is also being pursued by other companies and government entities.
• Actinium's clinical development strategy, particularly the Phase 2/3 trial design for Actimab-A, reflects a trend towards more efficient trial designs in the biotech industry.
• The company's collaboration with the NCI under a CRADA is similar to other biotech companies that leverage government partnerships to accelerate drug development.
• The company's Iomab-ACT program is targeting the rapidly growing cell and gene therapy market, which is also being pursued by other companies developing conditioning regimens for these therapies.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the uncertainty surrounding the Iomab-B regulatory pathway.
• Employees may be affected by the recent reduction in headcount.
• Patients with relapsed or refractory AML may experience delays in the availability of Iomab-B.
• Potential partners may be interested in the company's technology and pipeline, but may be cautious due to the regulatory challenges with Iomab-B.
• Suppliers may be affected by the company's need to secure additional sources of Ac-225 and other isotopes.

Next Steps

• Actinium will conduct a further meeting with the FDA to discuss the specifics of the additional head-to-head clinical trial required for Iomab-B.
• Actinium will seek a strategic partner for Iomab-B in the U.S. to advance the required clinical trials.
• Actinium will continue to advance the development of Actimab-A, including the Phase 2/3 clinical trial in combination with CLAG-M.
• Actinium expects to commence patient enrollment of the Iomab-ACT commercial CAR-T trial in the first quarter of 2025.
• Actinium will continue to develop Iomab-ACT based on early promising results.

Key Dates

Keywords

Iomab-B, Actimab-A, Iomab-ACT, AML, Antibody Radiation Conjugates, Radiotherapy, Clinical Trials, FDA, Ac-225, BMT, CAR-T, Oncology, Hematology, Biopharmaceutical